Phase I Study of KRN7000 in Patients With Solid Tumor Treated With a Weekly Intravenous Administration Schedule
18 Years
N/A
Both
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Trial Information
Phase I Study of KRN7000 in Patients With Solid Tumor Treated With a Weekly Intravenous Administration Schedule
OBJECTIVES: I. Determine the safety profile and maximum tolerated dose of KRN7000 in
patients with solid tumors. II. Assess the biological and immunological parameters that
would suggest the optimal biologically active dose of KRN7000 in these patients. III.
Determine the pharmacokinetics of KRN7000 at the different dose levels in these patients.
IV. Measure any antitumor activity in these patients treated with this regimen.
OUTLINE: This is a dose escalation study. Patients receive KRN7000 by slow intravenous
injection on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the
absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients each
receive escalating doses of KRN7000 until the maximum tolerated dose (MTD) is determined.
The MTD is defined as the dose at which at least 2 of 6 patients experience dose limiting
toxicity.
PROJECTED ACCRUAL: Approximately 40 patients will be accrued for this study within 18
months.
Inclusion Criteria
DISEASE CHARACTERISTICS: Histologically or cytologically proven solid tumor that is
refractory to conventional treatment or for which no curative or standard palliative
treatment exists No brain involvement or leptomeningeal disease
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG/WHO 0-2 Life
expectancy: At least 3 months Hematopoietic: WBC at least 4,000/mm3 Platelet count at
least 100,000/mm3 Lymphocyte count at least 600/mm3 Hepatic: Bilirubin less than 1.5 mg/dL
AST and ALT no greater than 2.5 times upper limit of normal No liver cirrhosis Hepatitis B
surface antigen negative Renal: Creatinine no greater than 1.4 mg/dL OR Creatinine
clearance at least 60 mL/min Cardiovascular: No New York Heart Association class III or IV
heart disease Immunologic: No immunodeficiency No autoimmune disease Other: Not pregnant
or nursing Negative pregnancy test Fertile patients must use effective contraception No
active infection No nonmalignant disease incompatible with study No prior alcoholism, drug
addiction, or psychotic disorders unless suitable for adequate follow up No cerebroside
metabolite abnormalities (e.g., Gaucher's disease) HIV negative
PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 months since prior immunotherapy No
concurrent cytokines Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for
nitrosoureas, mitomycin, and high dose chemotherapy) Endocrine therapy: Not specified
Radiotherapy: At least 4 weeks since prior radiotherapy (6 weeks for extensive
radiotherapy) No concurrent radiotherapy Surgery: Not specified Other: No other concurrent
investigational or antitumor drugs
Type of Study:
Interventional
Study Design:
Primary Purpose: Treatment
Principal Investigator
Giuseppe Giaccone, MD, PhD
Investigator Role:
Study Chair
Investigator Affiliation:
Free University Medical Center
Authority:
United States: Federal Government
Study ID:
EORTC-13972
NCT ID:
NCT00003985
Start Date:
September 1998
Completion Date:
Related Keywords:
- Lung Cancer
- Unspecified Adult Solid Tumor, Protocol Specific
- non-small cell lung cancer
- unspecified adult solid tumor, protocol specific
- Lung Neoplasms
- Neoplasms
Name | Location |
|---|
